Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for POXEL FRANCE (PXXLF : OTC)
 
 • Company Description   
Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company's product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France.

Number of Employees: 53

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.10 Daily Weekly Monthly
20 Day Moving Average: 25 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 0.69
52 Week High: $7.04
52 Week Low: $2.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.02% 0.23%
12 Week -63.95% -60.36%
Year To Date -61.68% -53.18%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Immeuble Le Sunway 259-261 Avenue Jean Jaures
-
Lyon,I0 69007
FRA
ph: 00-33-4-37-37-20-10
fax: 043-770-8815
investors@poxelpharma.com http://www.poxelpharma.com
 
 • General Corporate Information   
Officers
Thomas Kuhn - Chief Executive Officer
Pierre Legault - Chairman
Sebastien Bolze - Executive Vice President & Chief Operating Officer
Anne Renevot - Executive Vice President & Chief Financial Officer
Khoso Baluch - Director

Peer Information
POXEL FRANCE (CORR.)
POXEL FRANCE (RSPI)
POXEL FRANCE (CGXP)
POXEL FRANCE (BGEN)
POXEL FRANCE (GTBP)
POXEL FRANCE (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: F7S69W106
SIC: 8880
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 0.69
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.53 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.94
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©